The phase 2b ENLIVEN trial, a multicenter, randomized, double-blind, placebo-controlled study, included 222 patients with biopsy-confirmed NASH and F2-F3 fibrosis, assigned to receive pegozafermin at doses of 15 mg weekly, 30 mg weekly, 44 mg every 2 weeks, or placebo for 24 weeks
Many patients continue treatment long-term because the metabolic and appetite benefits become part of their health management plan
If burning persists beyond a few hours, contact your clinician
Recent research has highlighted the involvement of glutathione in various psychiatric and neurodegenerative disorders, underscoring its significance in neurological conditions and injuries
When to Be Concerned Frequent urination is not always a cause for alarm
A comprehensive review in Pharmacological Research confirms that skeletal muscle changes with GLP-1 treatment appear to be adaptive, aligning with what you would expect given the amount of weight lost (Pereira et al., 2025)